Premium
Characteristics of retinal vein occlusion (RVO) patients with macular edema who lasted remission more than 6 months after single injection of intravitreal bevacizumab
Author(s) -
Lee M.Y.
Publication year - 2016
Publication title -
acta ophthalmologica
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.534
H-Index - 87
eISSN - 1755-3768
pISSN - 1755-375X
DOI - 10.1111/j.1755-3768.2016.0274
Subject(s) - medicine , macular edema , visual acuity , bevacizumab , ophthalmology , retinal vein , occlusion , edema , diabetes mellitus , surgery , chemotherapy , endocrinology
Purpose To evaluate clinical characteristics of retinal veiin occlusion (RVO) patients with macular edema who lasted remission more than 6 months after single injection of intravitreal bevacizumab. Methods We retrospectively reviewed sixty eight eyes of 67 patients who have macular edema due to RVO. Group 1 included eyes lasted remission more than 6 months after single injection of intravitreal bevacizumab. Group 2 included eyes lasted macular edema even after two injections of intravitreal bevacizumab and needed intravitreal triamcinolone or ozurdex. Clinical characteristics including initial visual acuity, initial CMT (Central macular thickness) were compared between two groups. Results 44, 24, eyes were included in group 1, 2 respectively. Group 1 included 36 eyes of BRVO and 8 eyes of CRVO. Group 2 included 11 eyes of BRVO and 13 eyes of CRVO. Initial visual acuity was better in group 1 than group 2 (p = 0.023). Initial CMT was higher in group 2 (p = 0.006). Prevalence rate of diabetes were higher in group 2 (p = 0.002). Conclusions Our results suggest that weather the patient have a diabetes and initial visual acuity and CMT can be helpful in predicting the treatment response after intravitreal bevacizumab injection in these patients.